1. Angst J, Bowden CL, Calabrese JR, Chengappa R,
Goodwin G, Lecrubier Y, et al. ECNP consensus
meeting March 2000: NICE guidelines for
investigating efficacy in bipolar disorder.
Eur Neuropsychopharmacol 2001;11:79–88.
2. Murray CJ, Lopez AD. Global mortality, disability,
and the contribution of risk factors: Global
Burden of Disease Study. Lancet 1997;
349:1436–42.
3. Dinan TG. Lithium in bipolar mood disorder.
BMJ 2002;324:989–90.
4. Muller Oerlinghausen B, Berghofer A, Bauer M.
Bipolar disorder. Lancet 2002;359:241–7.
5. Daly I. Mania. Lancet 1997;349:1157–60.
6. Miller-Oerlinghausen B, Muser-Causemann B,
Volk J. Suicides and parasuicides in a high risk
patient group on and off lithium long-term
medication. J Affect Disord 1992;25:261–9.
7. Carlson GA, Strober M. Manic depressive-illness in
early adolescence: a study of clinical and
diagnostic characteristics in six cases. J Am Acad
Child Adolesc Psychiatry 1978;17:138–53.
8. Woznniak J, Biederman J, Mundy E, Mennin D,
Faraone SV. A pilot family study of childhoodonset
mania. J Am Acad Child Adolesc Psychiatry
1995;34:1577–83.
9. DeLong GR, Aldershof AL. Long-term experience
with lithium treatment in childhood: correlation
with clinical diagnosis. J Am Acad Child Adolesc
Psychiatry 1987;26:389–94.
10. Koegal P, Burman MA, Farr RK. The prevalence of
specific psychiatric disorders among homeless
individuals in the inner city of Los Angeles. Arch
Gen Psychiatry 1988;45:1085–92.
11. Angst J. The emerging epidemiology of
hypomania and bipolar II disorder. J Affect Disord
1998;50:143–51.
12. McGuffin P, Katz R. Nature, nurture and affective
disorder. In Deakin JWF, editor. The biology of
depression. London: Gaskell; 1986. pp. 26–51.
13. Nurnberger JI, Gershon E. Genetics. In Paykel ES,
editor. Handbook of affective disorders. 2nd ed. New
York: Churchill Livingstone; 1992. pp. 131–48.
14. Goodwin FK, Jamison KR. Manic-depressive illness.
New York: Oxford University Press; 1990.
15. Coryell W, Scheftner W, Keller M, Endicott J,
Maser J, Klerman GL. The enduring psychosocial
consequences of mania and depression. Am J
Psychiatry 1993;150:720–7.
16. Das Gupta R, Guest JF. Annual cost of bipolar
disorder to UK society. Br J Psychiatry 2002;
180:227–33.
17. British Medical Association, Royal Pharmaceutical
Society of Great Britain. British National Formulary.
London: BMA and Royal Pharmaceutical Society
of Great Britain; 2002. p. 43.
18. Moore NA, Tye NC, Axton MS, Risius FC. The
behavioral pharmacology of olanzapine, a novel
‘atypical’ antipsychotic agent. J Pharmacol Exp Ther
1992;262:545–51.
19. Keck PE, Jr, McElroy SL. Pharmacological
treatments for bipolar disorder. In Nathan PE,
Gorman JM, editors. A guide to treatments that work.
2nd ed. Oxford: Oxford University Press; 2002.
pp. 277–99.
20. Saller CF, Salama AI. Sequel: biochemical profile
of a potential atypical antipsychotic.
Psychopharmacology 1993;112:285–92.
21. Fariello R, Smith MC. Valproate: mechanisms of
action. In Schatzberg AF, editor. Antiepileptic drugs.
New York: Raven Press; 1989. pp. 567–75.
22. Chen G, Huang LD, Zeng WZ, Manji HK. Mood
stabilizers regulate cytoprotective and mRNAbinding
proteins in the brain: long-term effects on
cell survival and transcript stability. Int J
Neuropsychopharmacol 2001;4:47–64.
23. NHSCRD. Undertaking systematic reviews of research
on effectiveness: CRD’s guidance for carrying out or
commissioning reviews: CRD report 4. 2nd ed. York:
NHS Centre for Reviews and Dissemination; 2001.
24. Drummond MF, O’ Brien B, Stoddart GL,
Torrance GW. Methods for the economic evaluation of
health care programmes. 2nd ed. Oxford: Oxford
Medical Publications; 1997.
25. National Institute for Clinical Excellence.
Technical guidance for manufacturers and sponsors on
making a submission to a technology appraisal.
London: National Institute for Clinical Excellence;
2001.
26. AstraZeneca UK Ltd. The clinical and cost
effectiveness of newer drugs for the treatment of mania
associated with bipolar affective disorder: submission of
evidence from AstraZeneca UK Ltd regarding the
atypical antipsychotic quetiapine. Alderley Park,
Macclesfield: AstraZeneca UK Ltd; October 2002.
27. AstraZeneca UK Ltd. The clinical and cost effectiveness
of newer drugs for the treatment of mania associated with
bipolar affective disorder: submission of evidence from
AstraZeneca UK Ltd regarding the atypical antipsychotic
quetiapine. Alderley Park, Macclesfield: AstraZeneca
UK Ltd; November 2002.
28. Sachs G, Mullen JA, Devine NA, Sweitzer DE.
Quetiapine vs placebo as adjunct to mood
stabilizer in the treatment of acute mania [meeting
abstract]. Eur Neuropsychopharmacol 2002;
12 (Suppl 3):S235.
29. Mullen J, Paulsson B. Quetiapine in combination
with lithium or divalproex for the treatment of
mania associated with bipolar disorder. In Fifth
International Conference on Bipolar Disorder; 12–14
June 2003, Piitsburgh, PA.
30. Brecher M, Huizar K. Quetiapine monotherapy
for acute mania associated with bipolar disorder.
In Fifth International Conference on Bipolar Disorder,
12–14 June 2003, Pittsburgh, PA.
31. Jones M, Huizar K. Quetiapine monotherapy for
mania associated with bipolar disorder. In Fifth
International Conference on Bipolar Disorder, 12–14
June 2003, Pittsburgh, PA.
32. Jones M, Huizar K. Quetiapine monotherapy for
mania associated with bipolar disorder. In 166th
Annual Meeting of the American Psychiatric Association,
17–22 May 2003, San Francisco, CA.
33. DelBello MP, Schwiers ML, Rosenberg HL,
Strakowski SM. A double-blind, randomized,
placebo-controlled study of quetiapine as
adjunctive treatment for adolescent mania. J Am
Acad Child Adolesc Psychiatry 2002;41:1216–23.
34. Paulsson B, Huizar K. Quetiapine monotherapy
for the treatment of bipolar mania. In Fifth Annual
International Conference on Bipolar Disorder, 12–14
June 2003, Pittsburgh, PA.
35. Tohen M, Sanger TM, McElroy SL, Tollefson GD,
Chengappa KN, Daniel DG, et al. Olanzapine
versus placebo in the treatment of acute mania.
Olanzapine HGEH Study Group. Am J Psychiatry
1999;156:702–9.
36. Tohen M, Jacobs TG, Grundy SL, McElroy SL,
Banov MC, Janicak PG, et al. Efficacy of
olanzapine in acute bipolar mania: a double-blind,
placebo-controlled study. The Olanzipine
HGGW Study Group. Arch Gen Psychiatry 2000;
57:841–9.
37. Tohen M, Zhang F, Feldman PD, Evans AR,
Breier AF. Olanzapine versus haloperidol in the
treatment of acute mania [meeting abstract]. 2001
Annual Meeting of the American Psychiatric Association,
5–10 May 2001, New Orleans, LA.
38. Shi L, Namjoshi MA, Zhang F, Ghandi G, Edgell
ET, Tohen M, et al. Olanzapine versus haloperidol
in the treatment of acute mania: clinical outcomes,
health-related quality of life and work status. Int
Clin Psychopharmacol 2002;17:227–37.
39. Shi L, Namjoshi M, Tohen MF, Zhang F, Breier
AF, Edgell ET. Olanzapine versus haloperidol: a
prospective comparison of clinical and humanistic
outcomes in bipolar disorder [meeting abstract].
In 2001 Annual Meeting of the American Psychiatric
Association, 5–10 May 2001, New Orleans, LA.
40. Berk M, Ichim L, Brook S. Olanzapine compared
to lithium in mania: a double-blind randomized
controlled trial. Int Clin Psychopharmacol 1999;
14:339–43.
41. Tohen M, Chengappa KNR, Suppes T,
Zarate CA, Jr, Calabrese JR, Bowden CL, et al.
Efficacy of olanzapine in combination with
valproate or lithium in the treatment of mania in
patients partially nonresponsive to valproate or
lithium monotherapy. Arch Gen Psychiatry 2002;
59:62–9.
42. Meehan K, Zhang F, David S, Tohen M, Janicak P,
Small J, et al. A double-blind, randomized
comparison of the efficacy and safety of
intramuscular injections of olanzapine, lorazepam,
or placebo in treating acutely agitated patients
diagnosed with bipolar mania. J Clin
Psychopharmacol 2001;21:389–97.
43. Meehan K, Breier A, David SR, Koch KE, Rizk R,
Tohen M, et al. Efficacy and safety of
intramuscular (im) olanzapine versus im
lorazepam and im placebo in acutely agitated
patients diagnosed with mania associated with
bipolar disorder. Schizophr Res 2001;49:239.
44. Namjoshi M, Shi L, Zhang F, Edgell ET, Tohen MF,
Breier AF. Olanzapine versus haloperidol:
improvements in quality of life and compliance
with treatment in patients with bipolar disorder. In
2001 Annual Meeting of the American Psychiatric
Association, 5–10 May 2001, New Orleans, LA.
45. Tohen KF, Tohen M, Timpe TM, Risser R,
Chengappa KR, Suppes TR, et al. Efficacy of
olanzapine combined with mood stabilizers in the
treatment of bipolar disorder. Schizophr Res 2001;
49:248.
46. Tohen M, Jacobs TG, Meyers TM, Risser RC,
Keeter EL, Feldman PD, et al. Efficacy of
olanzapine combined with mood stabilizers in the
treatment of bipolar disorder. Int J
Neuropsychopharmacol 2000;3 (Suppl 1):S335.
47. Tohen M, Jacobs TG, Timpe TM, Risser RC,
Keeter EL, Chengappa KNR, et al. Efficacy of
olanzapine combined with valproate or lithium in
the treatment of bipolar disorder. Biol Psychiatry
2001;49:385.
48. Pope HG, Jr., McElroy SL, Keck PE, Jr, Hudson JI.
Valproate in the treatment of acute mania: a
placebo-controlled study. Arch Gen Psychiatry 1991;
48:62–8.
49. Bowden CL, Brugger AM, Swann AC, Calabrese JR,
Janicak PG, Petty F, et al. Efficacy of divalproex vs
lithium and placebo in the treatment of mania.
The Depakote Mania Study Group. JAMA 1994;
271:918–24.
50. Swann AC, Bowden CL, Morris D, Calabrese JR,
Petty F, Small J, et al. Depression during mania:
treatment response to lithium or divalproex.
Arch Gen Psychiatry 1997;54:37–42.
51. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC,
Morris DD. Differential effect of number of
previous episodes of affective disorder on response
to lithium or divalproex in acute mania. Am J
Psychiatry 1999;156:1264–6.
52. Bowden CL, Davis J, Morris D, Swann A, Calabrese
J, Lambert M, et al. Effect size of efficacy measures
comparing divalproex, lithium and placebo in
acute mania. Depress Anxiety 1997;6:26–30.
53. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Jr,
Russell JM. Safety and tolerability of oral loading
divalproex sodium in acutely manic bipolar
patients. J Clin Psychiatry 1999;60:815–18.
54. Kowatch RA, Suppes T, Carmody TJ, Bucci JP,
Hume JH, Kromelis M, et al. Effect size of lithium,
divalproex sodium, and carbamazepine in children
and adolescents with bipolar disorder. J Am Acad
Child Adolesc Psychiatry 2000;39:713–20.
55. McElroy SL, Keck PE, Stanton SP, Tugrul KC,
Bennett JA, Strakowski SM. A randomized
comparison of divalproex oral loading versus
haloperidol in the initial treatment of acute
psychotic mania. J Clin Psychiatry 1996;57:142–6.
56. Tohen M, Baker RW, Altshuler LL, Zarate CA,
Suppes T, Ketter TA, et al. Olanzapine versus
divalproex in the treatment of acute mania. Am J
Psychiatry 2002;159:1011–17.
57. Zajecka J, Weisler R, Sommerville KW, Tracy K,
Swann AC, Sachs G, et al. Divalproex sodium vs
olanzapine for the treatment of mania in bipolar
disorder. In 39th Annual Meeting of the American
College of Neuropsychopharmacology, 10–14
December 2000, San Juan, Puerto Rico. Nashville,
TN: Vanderbilt University Medical Center,
American College of Neuropsychopharmacology;
2000. p. 257.
58. Keck PE, Jr, Nabulsi AA, Taylor JL, Henke CJ,
Chmiel JJ, Stanton SP, et al. A pharmacoeconomic
model of divalproex semisodium vs. lithium in the
acute and prophylactic treatment of bipolar I
disorder. J Clin Psychiatry 1996;57:213–22.
59. Keck PE, Jr., McElroy SL, Strakowski SM, West SA,
Hawkins JM, Huber TJ, et al. Outcome and
comorbidity in first- compared with multipleepisode
mania. J Nerv Ment Dis 1995;183:320–4.
60. McElroy SL, Strakowski SM, Keck PE, Jr, Tugrul KL,
West SA, Lonczak HS. Differences and similarities
in mixed and pure mania. Compr Psychiatry 1995;
36:187–94.
61. Department of Health. Hospital episode statistics
(HES) 2000/01 [monograph online]. 2002. Available
at http://www.doh.gov.uk/hes/ [accessed 2002].
62. Briggs A, Goeree R, Blackhouse G, O’Brien B.
Probabilistic analysis of cost-effectiveness models:
choosing between treatment strategies for
gastroesophageal reflux disease. Med Decis Making
2002;22:290–308.
63. McAlistair F, Laupacis A, Wells G, Sackett D.
Users’ guide to the medical literature. XIX
Applying clinical trial results. B. Guidelines for
determining whether a drug is exerting (more
than) a class effect. JAMA 1999;282:1371–77.
64. Hasselblad V. Meta-analysis of multi-treatment
studies. Med Decis Making 1998;18:37–43.
65. Higgins J, Whitehead J. Borrowing strength from
external clinical trials in a meta-analysis. Stat Med
1996;15:2733–49.
66. Lumley T. Network meta-analysis for indirect
treatment comparisons. Stat Med 2002;21:2313–24.
67. Ades A. A chain of evidence with mixed comparisons:
models for multi-parameter evidence synthesis and
consistency of evidence. Paper presented to DEEM
workshop, 11–12 April, Oxford. Available at
http://www.ihs.ox.ac.uk/herc/DEEM/Ades.pdf
[accessed 2002].
68. Johannesson M, Weinstein M. On the decision
rules of cost-effectiveness analysis. J Health Econ
1993;12:459–67.
69. Van Hout B, Gordon G, Rutten F. Costs, effects
and C/E ratios alongside a clinical trial. Health
Econ 1994;3:309–19.
70. Fenwick E, Claxton K, Sculpher M. Representing
uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–89.
71. Maj M, Priozzi R, Kemali D. Long term outcome
of lithium prolaxis in patients initially classified as
complete responders. Neuropharmacology 1988;
98:535–8.
72. Allen D. Olanzapine in the treatment of acute
mania in the community. Psychiatr Bull R Coll
Psychiatr 1998;22:189–190. Available at
http://pb.rcpsych.org/.
73. Anon. Zyprexa: short-term treatment of acute
manic episodes of bipolar disorder. Formulary
2000;35:388–90.
74. Anon. Multicenter study confirms value of
divalproex for mania. Am J Hosp Pharm 1994;
51:388–90.
75. Anon. Disodium valproate: new preparation: an
alternative for acute mania after lithium failure or
intolerance. Prescrire Int 2001;10:113–15.
76. Anon. Combination therapy is most appropriate
for acute mania. Drugs Ther Perspect 1995;6:12–14.
77. Baetz M, Bowen RC. Efficacy of divalproex sodium
in patients with panic disorder and mood
instability who have not responded to conventional
therapy. Can J Psychiatry 1998;43:73–7.
78. Baker RW, Kinon BJ, Liu H, Richey A, Hill AL,
Bergstrom RF, et al. Effectiveness of rapid initial
dose escalation of oral olanzapine for acute
agitation [meeting abstract]. In Meeting of
American Psychiatric Association, 18–23 May 2002,
Philadelphia, PA, USA.
79. Baker RW, Tohen M, Risser RC, Stauffer VL,
Breier A, Tollefson GD. Depression during mania:
treatment response to olanzapine or placebo
[meeting abstract]. Eur Neuropsychopharmacol
2000;10:S246.
80. Baker RW, Milton DR, Tohen M, Stauffer VL,
Breier A. Olanzapine is not associated with
exacerbation of bipolar mania [meeting abstract].
Biol Psychiatry 2001;49 (Suppl 8):43S.
81. Baker RW, Milton DR, Tohen MF, Stauffer VL,
Breier AF. Olanzapine is not associated with
exacerbation of bipolar mania [meeting abstract].
In 52nd Meeting of Institute on Psychiatric Services,
25–29 October 2000, Philadelphia, PA.
82. Baker CB, Woods SW, Sernyak MJ. Costeffectiveness
of divalproex versus lithium. J Clin
Psychiatry 1997;58:363–4.
83. Bares M, Hrdlicka M, Propper L. Atypical
neuroleptic drug, olanzapine, in the treatment of
impaired mood. Prakt Lek 2000;80:329–32.
84. Berney A, Bryois C. Treatment of acute mania
using valproate: open study. Schweiz Arch Neurol
Psychiatr 1999;150:233–7.
85. Beyzarov EP. Antipsychotic drug receives
indication for bipolar disorder. Drug Topics 2000;
144:29.
86. Bhana N, Perry CM. Olanzapine: a review of its
use in the treatment of bipolar I disorder. CNS
Drugs 2001;15:871–904.
87. Bowden CL, Swann AC, Calabrese JR, McElroy SL,
Morris D, Petty F, et al. Maintenance clinical trials
in bipolar disorder: design implications of the
divalproex–lithium–placebo study. Psychopharmacol
Bull 1997;33:693–9.
88. Bowden CL. Dosing strategies and time course of
response to antimanic drugs. J Clin Psychiatry
1996;57 (Suppl 13):4–9; discussion, 10–12.
89. Bowden CL, Calabrese JR, McElroy SL, Gyulai L,
Wassef A, Petty F, et al. A randomized, placebocontrolled
12-month trial of divalproex and
lithium in treatment of outpatients with bipolar I
disorder. Divalproex Maintenance Study Group.
Arch Gen Psychiatry 2000;57:481–9.
90. Bowden CL. Efficacy of divalproex vs lithium and
placebo in mania: in reply. JAMA 1994;272:1006.
Available at http://jama ama-assn org/
91. Brasfield KH. Pilot study of divalproex sodium
versus valproic acid: drug acquisition costs versus
all related costs. Curr Ther Res Clin Exp 1999;
60:138–44.
92. Brown WA. A correction: efficacy of olanzapine in
acute bipolar mania: a double-blind, placebocontrolled
study. The Olanzipine HGGW Study
Group. Arch Gen Psychiatry 2002;59:91.
93. Brown S, Nejtek VA, Perantie DC, Bobadilla L.
Quetiapine in patients with bipolar disorder and
cocaine dependence. Biol Psychiatry 2001;49:178.
94. Calabrese JR, Shelton MD, Rapport DJ, Kujawa M,
Kimmel SE, Caban S. Current research on rapid
cycling bipolar disorder and its treatment. J Affect
Disord 2001;67:241–55.
95. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner
SC. Spectrum of efficacy of valproate in 78 rapidcycling
bipolar patients. J Clin Psychopharmacol
1992;12(Suppl.):53–6.
96. Carroll BT, Thalassinos A, Fawver JD. Loading
strategies in acute mania. CNS Spectr 2001;
6:919–22, 930.
97. Cavazzoni P, Berg PH, Baker RW, Evans AR,
Tohen M. Extrapyramidal symptoms of olanzapine
versus placebo or haloperidol in the treatment of
acute mania and contrasts to schizophrenia.
Schizophr Res 2002;53:169–70.
98. Chou JY. Drug treatment of acute mania. Drugs
Today 1992;28:119–30.
99. Conney J, Kaston B. Pharmacoeconomic and
health outcome comparison of lithium and
divalproex in a VA geriatric nursing home
population: influence of drug-related morbidity on
total cost of treatment. Am J Manag Care 1999;
5:197–204.
100. Cookson J. Use of antipsychotic drugs and lithium
in mania. Br J Psychiatry 2001;178
(Suppl 41):s148–56.
101. Dalkilic A, Diaz E, Baker CB, Pearsall HR, Woods
SW. Effects of divalproex versus lithium on length
of hospital stay among patients with bipolar
disorder. Psychiatr Serv 2000;51:1184–6.
102. Dardennes RM, Even C. Is divalproex a costeffective
alternative in the acute and prophylactic
treatment of bipolar I disorder? J Clin Psychiatry
1997;58:495–6.
103. David SR, Battaglia J, Alaka K, Meehan K, Wright
P. Calming versus sedative effects of IM olanzapine
in agitated patients [meeting abstract]. Biol
Pyschiatry 2002;51:197S.
104. Davis JM, Wang Z, Janicak PG. A quantitative
analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993;
29:175–81.
105. Dose M, Emrich HM. Acute mania: practical
therapeutic guidelines. CNS Drugs 1995;3:427–35.
106. Dunayevich E. Quetiapine in the treatment of
mania. Schizophr Res 2001;49:226.
107. Dunayevich E, Strakowski SM. Quetiapine for
treatment-resistant mania. Am J Psychiatry 2000;
157:1341.
108. Dunayevich E, McElroy SL. Atypical antipsychotics
in the treatment of bipolar disorder:
pharmacological and clinical effects. CNS Drugs
2000;13:433–41.
109. Ellenor G, Lohr JB, Ito M, Dishman B,
Gammariello A. The comparative efficacy of
divalproex low and high serum level in bipolar
disorder and schizophrenia. New Clinical Drug
Evaluation Unit Meeting 1995;563.
110. Emrich HM, Gunther R, Dose M. Current
perspectives in the pharmacopsychiatry of
depression and mania. Neuropharmacology 1983;
22:385–8.
111. Falsetti AE. Olanzapine: psychopharmacology,
clinical efficacy, and adverse effects. Hosp Pharm
1999;34:423–35.
112. Feldstein JH, Curtis JL. Update on the costs of
Depakote and Depakene. Ment Retard 1995;33:62.
113. Fellows L, Jones M, Mehnert A. Inpatient
treatment of bipolar disorder: a comparison of
outcomes with risperidone and olanzapine
[meeting abstract]. Eur Neuropsychopharmacol 2001;
11 (Suppl 3):S249.
114. Frankenburg FR, Zanarini MC. Divalproex sodium
treatment of women with borderline personality
disorder and bipolar II disorder: a double-blind
placebo-controlled pilot study. J Clin Psychiatry
2002;63:442–6.
115. Frazier JA, Biederman J, Jacobs TG, Tohen MF,
Toma V, Feldman PD, et al. Olanzapine in the
treatment of bipolar-disorder in juveniles.
Schizophr Res 2000;41:B49.
116. Frazier JA, Tohen M, Biederman J, Jacobs T,
Toma V, Feldman P. Olanzapine in the treatment
of juvenile bipolar disorder. Int J
Neuropsychopharmacol 2000;3 (Suppl 1):S330.
117. Frye MA, Altshuler LL, Szuba MP, Finch NN,
Mintz J. The relationship between antimanic agent
for treatment of classic or dysphoric mania and
length of hospital stay. J Clin Psychiatry 1996;
57:17–21.
118. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD,
Swann AC. A double-blind comparison of
valproate and lithium in the treatment of acute
mania. Am J Psychiatry 1992;149:108–11.
119. Garza-Trevino ES. Alternatives to lithium therapy
in the treatment of acute mania. Drugs Today 1998;
34:295–305.
120. Geddes J, Goodwin G. Bipolar disorder: clinical
uncertainty, evidence-based medicine and largescale
randomised trials. Br J Psychiatry 2001;
178 (Suppl 41):s191–4.
121. Gerner RH, Stanton A. Algorithm for patient
management of acute manic states: lithium,
valproate, or carbamazepine? J Clin
Psychopharmacol 1992;12:57s–63s.
122. Ghaemi SN. New treatments for bipolar disorder:
the role of atypical neuroleptic agents. J Clin
Psychiatry 2000;61 (Suppl 14):33–42.
123. Ghaemi SN, Sachs GS, Goodwin FK. Divalproex
vs. lithium in the treatment of bipolar disorder.
Biol Psychiatry 1999;45:204.
124. Ghaemi N. Erratum: the use of quetiapine for
treatment-resistant bipolar disorder (Annals of
Clinical Psychiatry (1999) 11 (137–140)). Ann Clin
Psychiatry 2000;12:63.
125. Ghaemi SN, Katzow JJ. The use of quetiapine for
treatment-resistant bipolar disorder: a case series.
Ann Clin Psychiatry 1999;11:137–40.
126. Goldberg JF, Altshuler LL, Frye M, Keck PE, Jr.
Pharmacoeconomics of lithium and divalproex
sodium in the treatment of bipolar disorder. In
Powell SM, editor. The Hatherleigh guide to
psychopharmacology. New York: Hatherleigh Press;
1999. pp. 141–67.
127. Goodwin G. Drug treatment in mania. Prescr J
1994;34:19–26.
128. Haddad P, Chaudhry I, Soni S. Adjunctive use of
olanzapine in the treatment of mania. Int J
Psychiatry Clin Pract 1999;3:213–15. Available at
www.tandf.co.uk/journals/md/13651501.html
129. Hamilton D. Medical minute. Zyprexa offers hope
in the treatment of manic depression. Los Angeles
Times 4 December 2000;Sect. S3.
130. Hellewell JSE. A continuing role for antipsychotics
in the treatment of bipolar disorders: the story so
far. Continuing Professional Development Bull
Psychiatry 2000;2:107–14.
131. Hilger E, Barnas C. Atypical antipsychotics in the
treatment of bipolar affective disorders. Fortschr
Neurol Psychiatr 2002;70:234–42.
132. Hilty DM, Brady KT, Hales RE. A review of bipolar
disorder among adults. Psychiatr Serv 1999;
50:201–13.
133. Hirschfeld RM, Weisler RH, Keck PE, Ahern E,
Revicki D. Cost-effectiveness evaluation of
divalproex sodium versus lithium in the treatment
of bipolar disorder [meeting abstract]. In 152nd
Annual Meeting of the American Psychiatric Association,
15–20 May 1999, Washington, DC; 1999. pp. 262–3.
134. Icovino J, Haddad H, Detoledo J. Carbamazepine
and sodium divalproex in the treatment of bipolar
and schizoaffective disorders in the mentally
retarded: a prospective study. Neurology 1994;
44 (Suppl 2):A401.
135. Jacobsen FM, Comas-Diaz L. Dose-severity
responses to divalproex in bipolar illness [meeting
abstract]. Clin Pharmacol Ther 1995;57:207.
136. Jagadheesan K. Olanzapine in acute bipolar
mania. Arch Gen Psychiatry 2002;59:188.
137. James ACD, Javaloyes AM. Practitioner review: the
treatment of bipolar disorder in children and
adolescents. J Child Psychol Psychiatry 2001;
42:439–49.
138. Janicak PG, Newman RH, Davis JM. Advances in
the treatment of mania and related disorders: a
reappraisal. Psychiatr Ann 1992;22:92–103.
139. Jann MW, Garrelts JC, Ereshefsky L, Saklad SR.
Alternative drug therapies for mania: a literature
review. Drug Intell Clin Pharm 1984;18:577–89.
140. Janowsky DS. New treatments of bipolar disorder.
Curr Psychiatry Rep 1999;1:111–13.
141. Jonnalagada JR, Norton JW. Acute dystonia with
quetiapine. Clin Neuropharmacol 2000;23:229–30.
142. Kafantaris V. Treatment of bipolar disorder in
children and adolescents. J Am Acad Child Adolesc
Psychiatry 1995;34:732–41.
143. Kafantaris V, Coletti DJ, Dicker R, Padula G,
Kane JM. Adjunctive antipsychotic treatment of
adolescents with bipolar psychosis. J Am Acad Child
Adolesc Psychiatry 2001;40:1448–56.
144. Kaiser CJ, Beyer JL, Siegel A, Kennedy JS,
Tohen K, Berg P, et al. Olanzapine, divalproex,
and placebo treatment comparison of older adult
acute mania. Am J Geriatr Psychiatry 2002;10:99.
145. Keck PE Jr, McElroy SL. Clinical
pharmacodynamics and pharmacokinetics of
antimanic and mood-stabilizing medications.
J Clin Psychiatry 2002;63:3–11.
146. Keck PE, Jr, McElroy SL, Stanton SP, Bennett JA.
Pharmacoeconomic aspects of the treatment of
bipolar disorder. Psychiatr Ann 1996;
26 (7 Suppl):S449–53.
147. Keck PE, Jr, McElroy SL, Bennett JA. Healtheconomic
implications of the onset of action of
antimanic agents. J Clin Psychiatry 1996;
57 (Suppl 13):13–18; discussion, 19–22.
148. Keck PE, Martin J, Thomas JH, Allen MH,
Hirschfeld RM, Sommerville K. Safety and
efficacy of oral loading divalproex sodium in
acutely manic bipolar patients [meeting abstract].
In 152nd Annual Meeting of the American Psychiatric
Association, 15–20 May 1999, Washington, DC
p. 192.
149. Keck PE, Jr, Welge JA, McElroy SL, Arnold LM,
Strakowski SM. Placebo effect in randomized,
controlled studies of acute bipolar mania and
depression. Biol Psychiatry 2000;47:748–55.
150. Keck PE, Jr, McElroy SL, Strakowski SM, Soutullo
CA. Antipsychotics in the treatment of mood
disorders and risk of tardive dyskinesia. J Clin
Psychiatry 2000;61 (Suppl 4):33–8.
151. Keck PE, Jr, Mendlwicz J, Calabrese JR, Fawcett J,
Suppes T, Vestergaard PA, et al. A review of
randomized, controlled clinical trials in acute
mania. J Affect Disord 2000;59 (Suppl 1):S31–7.
152. Kennedy JS, Bymaster FP, Schuh L, Calligaro DO,
Nomikos G, Felder CC, et al. A current review of
olanzapine’s safety in the geriatric patient: from
pre-clinical pharmacology to clinical data. Int J
Geriatr Psychiatry 2001;16 (Suppl 1):S33–61.
153. Kerwin R. Olanzapine was more effective than
lorazepam at 2 hours but not at 24 hours in
bipolar mania with acute agitation. Evid Based
Ment Health 2002;5:18.
154. Ketter TA, Wang PW, Winsberg ME, Sachs N,
Tate DL, Strong CM, et al. Baseline hypofrontality
and divalproex response in bipolar disorders. Biol
Psychiatry 2000;47:412.
155. Kravitz HM, Fawcett J. Efficacy of divalproex vs
lithium and placebo in mania. JAMA 1994;
272:1005–6.
156. Kupka RW, Nolen WA, Altshuler LL, Denicoff KD,
Frye MA, Leverich GS, et al. The Stanley
Foundation Bipolar Network. 2. Preliminary
summary of demographics, course of illness and
response to novel treatments. Br J Psychiatry 2001;
178 (Suppl 41):s177–83.
157. Lacerda ALT, Soares JC, Tohen M. The role of
atypical antipsychotic agents in the treatment of
bipolar disorder: a literature review. Rev Bras
Psiquiatr 2002;24:34–43.
158. Lemoine P, Fondarai J, Faivre T. Valpromide
increases amplitude of heart rate circadian rhythm
in remitted bipolar and unipolar disorders: a
placebo-controlled study. Eur Psychiatry 2000;
15:424–32.
159. Levine J, Chengappa KNR, Parepally H. Side
effect profile of enteric-coated divalproex sodium
versus valproic acid. J Clin Psychiatry 2000;
61:680–1.
160. Licht RW. Drug treatment of mania: a critical
review. Acta Psychiatr Scand 1998;97:387–97.
161. Licht RW. Typical and atypical antipsychotics in
bipolar disorder. Acta Neuropsychiatr 2000;
12:115–19.
162. Licht RW. Limitations in randomised controlled
trials evaluating drug effects in mania. Eur Arch Psychiatry Clin Neurosci 2001;251:66–71.
163. Madhusoodanan S, Sinha S, Brenner R, Gupta S,
Bogunovic O. Use of olanzapine for elderly
patients with psychotic disorders: a review. Ann
Clin Psychiatry 2001;13:201–13.
164. Masand PS, Wang X, Manjooran J, Schwartz T,
Saba M, Hardoby W, et al. Comparison of
risperidone and olanzapine in bipolar and
schizoaffective disorders [meeting abstract]. Biol
Psychiatry 2000;47 (Suppl 8):90S.
165. Maggi JD, Halman MH. The effect of divalproex
sodium on viral load: a retrospective review of
HIV-positive patients with manic syndromes. Can J
Psychiatry 2001;46:359–62.
166. Martinez JM, Russell JM, Hirschfeld RM.
Tolerability of oral loading of divalproex sodium
in the treatment of acute mania. Depress Anxiety
1998;7:83–6.
167. McClellan J, Werry J. Practice parameters for the
assessment and treatment of children and
adolescents with bipolar disorder. American
Academy of Child and Adolescent Psychiatry. J Am
Acad Child Adolesc Psychiatry 1997;36:157s–76s.
168. McElroy SL, Keck PE, Jr. Pharmacologic agents for
the treatment of acute bipolar mania. Biol
Psychiatry 2000;48:539–57.
169. Mehnert A, Jones M. Risperidone and olanzapine
in inpatient treatment of bipolar disorder
[meeting abstract]. Eur Psychiatry 2001;
17 (Suppl 1):105s.
170. Miller DS, Yatham LN, Lam RW. Comparative
efficacy of typical and atypical antipsychotics as
add-on therapy to mood stabilizers in the
treatment of acute mania. J Clin Psychiatry 2001;
62:975–80.
171. Milton DR, Baker RW, Stauffer VL, Tohen M,
Breier A. Olanzapine is not associated with
exacerbation of bipolar mania [meeting abstract].
In Annual Meeting of the American Psychiatric
Association, 5–10 May 2001, New Orleans, LA.
172. Müller-Oerlinghausen B, Retzow A. Treatment of
acute manic episodes with valproate as an adjunct
to neuroleptic medication [meeting abstract]. In
9th Congress of the Association of European
Psychiatrists, 20–24 September 1998, Copenhagen.
p. 204s.
173. Müller Oerlinghausen B, Retzow A, Henn FA,
Giedke H, Walden J. Valproate as an adjunct to
neuroleptic medication for the treatment
of acute episodes of mania: a prospective,
randomized, double-blind, placebo-controlled,
multicenter study. European Valproate Mania
Study Group. J Clin Psychopharmacol
2000;20:195–203.
174. Namjoshi MA, Rajamannar G, Jacobs T, Sanger
TM, Risser R, Tohen MF, et al. Economic, clinical,
and quality-of-life outcomes associated with
olanzapine treatment in mania: results from a
randomized controlled trial. J Affect Disord 2002;
69:109–18.
175. Namjoshi M, Rajamannar G, Risser R, Tohen M,
Breier A. Impact of olanzapine added to lithium
or valproate on the quality of life of patients with
bipolar disorder. Int J Neuropsychopharmacol 2000;
3 (Suppl 1):S235.
176. Namjoshi M, Rajamannar G, Jacobs T, Feldman P,
Sanger T, Tohen M, et al. Clinical, humanistic, and
economic outcomes associated with long-term
treatment of mania with olanzapine [meeting
abstract]. Int J Neuropsychopharmacol 2000;
3 (Suppl 1):S332.
177. Namjoshi M, Rajamannar G, Jacobs TG, Feldman
PD, Sanger TM, Tohen MF, et al. Clinical,
humanistic and economic outcomes associated with
long-term olanzapine treatment of mania [meeting
abstract]. In 153rd Annual Meeting of the American
Psychiatric Association, 13–18 May 2000, Chicago, IL.
178. Namjoshi M, Jacobs T, Sanger TM, Gannon KS,
Tohen M, Breier A. Changes in health-related
quality of life of patients with bipolar disorder
treated with olanzapine. Eur Neuropsychopharmacol
1999;9 (Suppl 5):S245–6.
179. Namjoshi M, Risser RC, Shi L, Edgell ET, Tohen
MF, Breier AF. Impact of olanzapine added to
lithium or valproate on the quality of life of
patients with bipolar disorder. In 2001 Annual
Meeting of the American Psychiatric Association, 5–10
May 2001, New Orleans, LA.
180. Noaghiul S, Narayan M, Nelson JC. Divalproex
treatment of mania in elderly patients. Am J Geriatr
Psychiatry 1998;6:257–62.
181. Ozcan Y, Ozcan ME, Boztepe AV, Karlidag R.
Akut manide lityum, karbamazepin ve sodyum
valproatyn klinik etkinliginin karsylastyrylmasy: bir
oen calysma [Comparison of the clinical efficacy of
lithium, carbamazepine and sodium valproate in
acute mania: preliminary results]. Klin
Psikofarmakol Buelt 1999;9:203–7.
182. Ozcan ME, Boztepe AV. Lithium, carbamazepine
and valproate in acute mania. Klin Psikofarmakol
Buelt 2001;11:90–5.
183. Papatheodorou G, Kutcher SP. Divalproex
sodium treatment in late adolescent and young
adult acute mania. Psychopharmacol Bull
1993;29:213–19.
184. Papatheodorou G, Kutcher SP, Katic M, Szalai JP.
The efficacy and safety of divalproex sodium in
the treatment of acute mania in adolescents and
young adults: an open clinical trial. J Clin
Psychopharmacol 1995;15:110–16.
185. Piepho RW. Cardiovascular effects of
antipsychotics used in bipolar illness. J Clin
Psychiatry 2002;63 (Suppl 4):20–3.
186. Poolsup N, Li Wan Po A, de Oliveira IR.
Systematic overview of lithium treatment
in acute mania. J Clin Pharmacol Ther 2000;25:
139–56.
187. Post RM, Denicoff KD, Frye MA, Leverich GS.
Algorithms for bipolar mania. Mod Probl
Pharmacopsychiatry 1997;25:114–45.
188. Price PL. Olanzapine to treat the acute mania of
bipolar disorder. S D J Med 2000;53:523.
189. Procyshyn RM, Zerjav S. Drug utilization patterns
and outcomes associated with in-hospital
treatment with risperidone or olanzapine. Clin
Ther 1998;20:1203–17.
190. Reddy YCJ, Srinath S. Juvenile bipolar disorder.
Acta Psychiatr Scand 2000;102:162–70.
191. Rossler W. Cui bono or who needs health
economics? Psychiatr Prax 2001:S29–31.
192. Sachs GS, Printz DJ, Kahn DA, Carpenter D,
Docherty JP. Medication treatment of bipolar disorder
2000. Minneapolis: Healthcare Information
Programs, McGraw-Hill Healthcare Information
Group; 2000.
193. Sachs GS, Grossman F, Ghaemi SN, Okamoto A,
Bowden CL. Combination of a mood stabilizer
with risperidone or haloperidol for treatment of
acute mania: a double-blind, placebo-controlled
comparison of efficacy and safety. Am J Psychiatry
2002;159:1146–54.
194. Sajatovic M, Gerhart C, Semple W. Association
between mood-stabilizing medication and mental
health resource use in the management of acute
mania. Psychiatr Serv 1997;48:1037–41.
195. Sanger TM, Tohen M, Tollefson GD, McElroy SL,
Greaney MG, Toma V. Olanzapine vs placebo in
the treatment of acute Mania [meeting abstract].
Schizophr Res 1998;29:152.
196. Sanger T, Tohen MF, Jacobs T, Gannon KS,
Greaney M, Tollefson GD. Long-term olanzapine
treatment of mania [meeting abstract]. In 152nd
Annual Meeting of the American Psychiatric
Association, 15–20 May 1999, Washington, DC.
p. 190.
197. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA,
Greaney MG, Tohen MF. Long-term olanzapine
therapy in the treatment of bipolar I disorder: an
open-label continuation phase study. J Clin
Psychiatry 2001;62:273–81.
198. Sanger T, Tohen M, Tollefson G, David S, Greaney
M. Olanzapine versus placebo in rapid-cycling
bipolar disorder [meeting abstract]. Eur
Neuropsychopharmacol 1998;8 (Suppl 2):S227.
199. Schneider RK. Divalproex did not differ from
placebo or lithium in preventing recurrence of
new mood episodes in bipolar I disorder,
remission phase. Evid Based Ment Health 2001;4:9.
200. Schwartz TL, Boylan D, Kuhles ID, Gupta S,
Chengappa KNR, Parepally H, et al. Clinical
effectiveness of divalproex sodium in lithium
carbonate refractory Bipolar spectrum patients.
Pharmacy and Therapeutics 2000;25:410–17.
201. Segal J, Walton S, Clark H, Berk M.
Pharmacotherapy of mania: a review. Int J
Psychiatry Clin Pract 2000;4:171–93.
202. Shi L, Zhu B, Namjoshi M, Tunis S, Baker R,
Tohen M, et al. Improvement in health-related
quality of life was associated with antidepressant
property: evidence from an acute mania clinical
trial of olanzapine versus divalproex [meeting
abstract]. In Annual Meeting of American
Psychiatric Association; 18–23 May 2002,
Philadelphia, PA.
203. Solomon DA, Keitner GI, Miller IW, Shea MT,
Keller MB. Course of illness and maintenance
treatments for patients with bipolar disorder.
J Clin Psychiatry 1995;56:5–13.
204. Solomon DA, Ryan CE, Keitner GI, Miller IW,
Shea MT, Kazim A, et al. A pilot study of lithium
carbonate plus divalproex sodium for the
continuation and maintenance treatment of
patients with bipolar I disorder. J Clin Psychiatry
1997;58:95–9.
205. Steffens DC, Krishnan KR. Decision model for the
acute treatment of mania. Depress Anxiety 1996;
4:289–93.
206. Strakowski SM, DelBello MP, Adler CM.
Comparative efficacy and tolerability of drug
treatments for bipolar disorder. CNS Drugs
2001;15:701–18.
207. Swann AC. Prediction of treatment response in
acute mania: controlled clinical trials with
divalproex. Encephale 2001;27:277–9.
208. Tohen M, Chengappa KNR, Suppes T, Baker RW,
Risser RC, Evans AR, et al. Olanzapine combined
with mood stabilizers in prevention of recurrence
in bipolar disorder: an 18 month study [meeting
abstract]. In 23rd CINP Congress; 23–27 June 2002,
Montreal Collegium Internationale Neuro-
Psychopharmacologium.
209. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C,
Sanger T, et al. A meta-analysis of the use of
typical antipsychotic agents in bipolar disorder.
J Affect Disord 2001;65:85–93.
210. Tohen M, Zhang F, Keck PE, Feldman PD, Risser
RC, Tran PV, et al. Olanzapine versus haloperidol
in schizoaffective disorder, bipolar type. J Affect
Disord 2001;67:133–40.
211. Tohen M, Chengappa KNR, Suppes T, Baker RW,
Risser RC, Evans AR, et al. Olanzapine versus
haloperidol in the treatment of acute mania. Biol
Psychiatry 2002;51:541.
212. Tohen M, Zarate CA, Jr. Antipsychotic agents and
bipolar disorder. J Clin Psychiatry 1998;
59 (Suppl 1):38–48; discussion, 49.
213. Tohen M, Jacobs TG, Feldman PD. Onset of action
of antipsychotics in the treatment of mania. Bipolar
Disord 2000;2:261–8.
214. Tohen M, Grundy S. Management of acute mania.
J Clin Psychiatry 1999;60 (Suppl 5):31–4;
discussion, 35–6.
215. Tohen M, Jacobs TG, Grundy SL, McElroy SL,
Banov MC, Janicak PG, et al. Efficacy of
olanzapine in acute bipolar mania: a double-blind,
placebo-controlled study. Rev Psiquiatr Clin 2001;
28:218.
216. Tohen M, Risser R, Grundy SL. Olanzapine in
acute bipolar mania: in reply. Arch Gen Psychiatry
2002;59:188.
217. Toren P, Laor N, Weizman A. Use of atypical
neuroleptics in child and adolescent psychiatry.
J Clin Psychiatry 1998;59:644–56.
218. Townes P, Swartz CM. Comparison of valproic acid
and lithium in mania. J Clin Psychiatry 1997;
58:273–4.
219. Vasudev K, Goswami U, Kohli K. Carbamazepine
and valproate monotherapy: feasibility, relative
safety and efficacy, and therapeutic drug
monitoring in manic disorder. Psychopharmacology
2000;150:15–23.
220. Woods SW. The economic burden of bipolar
disorder. J Clin Psychiatry 2000;
61 (Suppl 13):38–41.
221. Woods SW. Classic mania: treatment response to
divalproex or lithium. Arch Gen Psychiatry 1998;
55:1050.
222. Yatham LN, Kusumakar V, Parikh SV, Haslam DRS,
Matte R, Sharma V, et al. Bipolar depression:
treatment options. Can J Psychiatry 1997;
42 (Suppl 2):87s–91s.
223. Young LT, Joffe RT, Robb JC, MacQueen GM,
Marriott M, Patelis Siotis I. Double-blind
comparison of addition of a second mood
stabilizer versus an antidepressant to an initial
mood stabilizer for treatment of patients with
bipolar depression. Am J Psychiatry 2000;157:124–6.
224. Zarate CA, Jr, Tohen M, Narendran R,
Tomassini EC, McDonald J, Sederer M, et al. The
adverse effect profile and efficacy of divalproex
sodium compared with valproic acid: a
pharmacoepidemiology study. J Clin Psychiatry
1999;60:232–6.
225. Zhu B, Lage MJ, Shi L, Tunis S, Tohen M. Longterm
quality-of-life and economic outcomes
associated with the use of olanzapine versus
divalproex for acute mania [meeting abstract]. Eur
Neuropsychopharmacol 2001;11 (Suppl 3):S260.
226. Tohen M, Sanger T, Tollefson GD, McElroy SL,
Greaney MG, Toma V. Experience using
olanzapine in the treatment of acute bipolar
mania [meeting abstract]. In 151st Annual Meeting
of the American Psychiatric Association, 30 May–4 June
1998, Toronto. p. 306.
227. Tohen M, Sanger TM, McElroy SL, Tollefson GD,
Grundy SL, Greaney M, et al. Olanzapine versus
placebo in the treatment of acute mania [meeting
abstract]. Eur Neuropsychopharmacol 1998;
8 (Suppl 2):S178.
228. Sanger TM, Tohen M, Tollefson GD, Jacobs T,
David S. Olanzapine vs. placebo in rapid-cycling
bipolar disorder [meeting abstract]. Schizophr Res
1998;29:152.
229. Toben M, Zarate C, Jr, Sanger IM. A placebocontrolled
trial of olanzapine in psychotic or nonpsychotic
acute mania [meeting abstract]. Schizophr
Res 1998;29:204.
230. Tohen M, Jacobs T, Sanger TM, Grundy S,
Greaney M, Toma V, et al. Safety of the novel
antipsychotic olanzapine in the acute treatment of
bipolar I disorder. Schizophr Res 1999;1:358.
231. Tohen M, Jacobs T, Gannon KS, Sanger TM,
Greaney M, Toma V, et al. Long-term olanzapine
treatment: cognitive and mood improvement in
psychotic and nonpsychotic manic patients.
Schizophr Res 1999;36:299.
232. Tohen M, Baker RW, Altshuler L, Zarate CA,
Suppes T, Ketter TA, et al. Olanzapine versus
divalproex sodium for the treatment of acute
mania and maintenance of remission: a 47-week
study. Biol Psychiatry 2002;51:208.
233. Merideth C, Sommerville KW, Zajecka J, Tracy K,
Swann AC, Sachs G, et al. Divalproex sodium vs.
Olanzapine for the treatment of mania in bipolar
disorder: effects on body weight change and
related outcomes. In 39th Annual Meeting of the
American College of Neuropsychopharmacology,
10–14 December 2000, San Juan, Puerto Rico.
Vanderbilt university Medical Center, American
College of Neuropsychopharmacology; 2000.
p. 258.